for females ages 18 years and up (full criteria)
at Orange, California and other locations
study started
completion around



This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 106 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo.

Official Title

A Two-stage, Randomized, Controlled Trial Comparing the Safety and Efficacy of Iltamiocel With Placebo in the Treatment of Female Participants With Chronic Fecal Incontinence and a History of Obstetric Anal Sphincter Injury (DigniFI)


Chronic fecal incontinence (FI) is the recurrent unintended passage of mucus and/or liquid or solid stool for at least 6 months. Iltamiocel is an investigational cell therapy product that involves a medical procedure in which a participant's own muscle cells are collected, processed, and then injected into the tissues of the external anal sphincter.

This is a double-blind randomized study, which means neither the participant, nor the study doctor will know which treatment group the participant will be in. Participants who are randomly chosen to receive injection with placebo will have the option to receive an injection with their cells after completion of the blinded portion of their study participation (12 months).


Fecal Incontinence, Obstetric Trauma, Obstetric Injury, Cell Therapy, Anal Incontinence, Rectal Diseases, Intestinal Diseases, Gastrointestinal Diseases, Bowel Incontinence, Iltamiocel


You can join if…

Open to females ages 18 years and up

  • Adult female ≥ 18 years of age who has primary symptoms of fecal incontinence (FI) for at least 12 months.
  • History of obstetric anal sphincter injury (e.g., episiotomy, perineal tear).
  • Failed conservative treatment (e.g., dietary modification, antidiarrheal medications, pelvic floor muscle training, biofeedback) for at least 6 months prior to enrollment.
  • Has a Cleveland Clinic Florida Incontinence Score (CCFIS) ≥9 at Baseline.
  • Must be willing and able to comply with the study procedures, be mentally competent and able to understand all study requirements, and must agree to read and sign the informed consent form prior to any study-related procedures.

You CAN'T join if...

  • Has an implanted stimulation neuromodulation system (sacral or tibial) and symptoms are unstable as determined by the physician.
  • Is pregnant or planning to become pregnant within the next 2 years.
  • Has known rectal sensory dysfunction (e.g., hypersensitivity or hyposensitivity).
  • Has an obstetric anal sphincter injury (e.g., episiotomy, perineal tear) within 1 year previous to study enrollment.
  • Patient BMI ≥ 35.
  • Has a history of cancer in the colorectal or pelvic organs within 5 years prior to study enrollment.
  • Any cancer that has undergone treatment within the past 12 months.
  • Has an established diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or current intestinal stoma.
  • Has grade III/IV hemorrhoids.
  • Has chronic diarrhea at the time of Screening.
  • Has chronic constipation at the time of Screening.
  • Has significant pelvic floor prolapse, significant genitourinary prolapse beyond the introitus, significant symptomatic rectocele, or evidence of significant rectal evacuation disorder leading to post-defecatory leakage.


  • UC Irvine Medical Center in progress, not accepting new patients
    Orange California 92868 United States
  • Prestige Medical Group accepting new patients
    Santa Ana California 92705 United States
  • Ochsner Health accepting new patients
    New Orleans Louisiana 70121 United States


accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
Cook MyoSite
Phase 3 Fecal Incontinence Research Study
Study Type
Expecting 200 study participants
Last Updated